Effectiveness of ERAS on Postoperative Recovery After Minimally Invasive Gastrectomy
Launched by SEOUL NATIONAL UNIVERSITY HOSPITAL · May 14, 2025
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how an "Enhanced Recovery After Surgery" (ERAS) program can help patients recover better after a specific type of surgery called minimally invasive gastrectomy, which is performed to treat gastric cancer. The goal is to see if following this ERAS protocol can increase the number of patients who are ready to go home after surgery.
To participate in this trial, you need to be an adult (19 years or older) scheduled for a laparoscopic or robotic gastrectomy for gastric cancer. You should also be in good health, as defined by certain medical standards. During the study, participants will follow the ERAS program and will be monitored to see how well they recover after surgery. It's important to know that you will need to provide written consent to take part and complete some questionnaires about your experience. This trial is not yet recruiting participants, but it aims to help improve recovery for future patients undergoing this type of surgery.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adults aged ≥19 years scheduled to undergo elective laparoscopic or robotic gastrectomy for gastric cancer
- • American Society of Anesthesiologists physical status classification I to III
- • Ability to provide written informed consent, demonstrate understanding of the study protocol, and complete patient-reported outcome measures appropriately
- Exclusion Criteria:
- • Requirement for resection of organs other than the stomach during surgery (except for cholecystectomy)
- • History of upper abdominal surgery (except for cholecystectomy)
- • Known hypersensitivity to fentanyl, ropivacaine, acetaminophen, or non-steroidal anti-inflammatory drugs
- • Determined by the investigator or study personnel to be otherwise unsuitable for participation in the study
About Seoul National University Hospital
Seoul National University Hospital (SNUH) is a leading medical institution in South Korea, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent clinical trial sponsor, SNUH integrates cutting-edge scientific inquiry with patient-centered care, facilitating the development of novel therapies and treatment protocols. The hospital boasts a diverse range of specialized departments and a robust infrastructure for conducting clinical studies, ensuring rigorous adherence to ethical standards and regulatory compliance. By fostering collaboration among multidisciplinary teams, SNUH aims to contribute significantly to global medical advancements and improve patient outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Seongnam, , Korea, Republic Of
Daejeon, , Korea, Republic Of
Seoul, , Korea, Republic Of
Goyang, , Korea, Republic Of
Busan, , Korea, Republic Of
Seoul, , Korea, Republic Of
Seoul, , Korea, Republic Of
Suwon, , Korea, Republic Of
Daegu, , Korea, Republic Of
Seoul, , Korea, Republic Of
Patients applied
Trial Officials
Do Joong Park, MD, PhD
Principal Investigator
Seoul National University Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported